Literature DB >> 23799159

RAS signaling pathways, mutations and their role in colorectal cancer.

Kypros Zenonos1, Katy Kyprianou.   

Abstract

Two of the main cellular pathways in which the RAS protein operates are the mitogen-activated protein kinases (MAPK) and phosphoinositide-3 kinase (PI3K) pathways. In a normal cell, these are important in controlling several functions, such as cell growth and survival. It becomes self-evident that these events will be disrupted in a malignant cell with a deregulated MAPK or PI3K pathway. Mutations in genes involved in these pathways and interacting with RAS, as well as RAS itself will be discussed. The second part of this review concentrates on how crucial RAS signaling is in colorectal cancer progression, with references to treatment response and prognosis when RAS or other related mutations are present.

Entities:  

Keywords:  Colorectal neoplasms; Genes; Mitogen-activated protein kinase signaling system; RAS; Therapeutics

Year:  2013        PMID: 23799159      PMCID: PMC3682174          DOI: 10.4251/wjgo.v5.i5.97

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  29 in total

Review 1.  Signaling interplay in Ras superfamily function.

Authors:  Natalia Mitin; Kent L Rossman; Channing J Der
Journal:  Curr Biol       Date:  2005-07-26       Impact factor: 10.834

Review 2.  Ras, PI(3)K and mTOR signalling controls tumour cell growth.

Authors:  Reuben J Shaw; Lewis C Cantley
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

Review 3.  Colorectal cancer and RASSF family--a special emphasis on RASSF1A.

Authors:  Maria Sofia Fernandes; Fátima Carneiro; Carla Oliveira; Raquel Seruca
Journal:  Int J Cancer       Date:  2012-07-14       Impact factor: 7.396

Review 4.  Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.

Authors:  Uzma Asghar; Eliza Hawkes; David Cunningham
Journal:  Clin Colorectal Cancer       Date:  2010-12       Impact factor: 4.481

Review 5.  Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

Authors:  Sergio Rizzo; Giuseppe Bronte; Daniele Fanale; Lidia Corsini; Nicola Silvestris; Daniele Santini; Gaspare Gulotta; Viviana Bazan; Nicola Gebbia; Fabio Fulfaro; Antonio Russo
Journal:  Cancer Treat Rev       Date:  2010-11       Impact factor: 12.111

6.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Authors:  Eric W Joseph; Christine A Pratilas; Poulikos I Poulikakos; Madhavi Tadi; Weiqing Wang; Barry S Taylor; Ensar Halilovic; Yogindra Persaud; Feng Xing; Agnes Viale; James Tsai; Paul B Chapman; Gideon Bollag; David B Solit; Neal Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-28       Impact factor: 11.205

Review 7.  The RASSF1A tumor suppressor.

Authors:  Howard Donninger; Michele D Vos; Geoffrey J Clark
Journal:  J Cell Sci       Date:  2007-09-15       Impact factor: 5.285

8.  Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous MLH1 mutation.

Authors:  Steven Gallinger; Melyssa Aronson; Katayoon Shayan; Elyanne M Ratcliffe; Justin T Gerstle; Patricia C Parkin; Heidi Rothenmund; Marina Croitoru; Ewa Baumann; Peter R Durie; Rosanna Weksberg; Aaron Pollett; Robert H Riddell; Bo Y Ngan; Ernest Cutz; Alain E Lagarde; Helen S L Chan
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

9.  Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.

Authors:  Stephan E Baldus; Karl-L Schaefer; Rainer Engers; Dinah Hartleb; Nikolas H Stoecklein; Helmut E Gabbert
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

10.  HER 2/neu protein expression in colorectal cancer.

Authors:  B Schuell; T Gruenberger; W Scheithauer; Ch Zielinski; F Wrba
Journal:  BMC Cancer       Date:  2006-05-08       Impact factor: 4.430

View more
  41 in total

1.  The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function.

Authors:  Anbarasu Kumaraswamy; Anitha Mamidi; Pavitra Desai; Ananthi Sivagnanam; Lakshmi Revathi Perumalsamy; Chandrasekaran Ramakrishnan; Michael Gromiha; Krishnaraj Rajalingam; Sundarasamy Mahalingam
Journal:  J Biol Chem       Date:  2018-08-23       Impact factor: 5.157

Review 2.  Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.

Authors:  Shaheedul A Sami; Noureldien H E Darwish; Amanda N M Barile; Shaker A Mousa
Journal:  Curr Treat Options Oncol       Date:  2020-01-13

3.  Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).

Authors:  Vicente Morales-Oyarvide; Chen Yuan; Ana Babic; Sui Zhang; Donna Niedzwiecki; Jennie C Brand-Miller; Laura Sampson-Kent; Xing Ye; Yanping Li; Leonard B Saltz; Robert J Mayer; Rex B Mowat; Renaud Whittom; Alexander Hantel; Al Benson; Daniel Atienza; Michael Messino; Hedy Kindler; Alan Venook; Shuji Ogino; Kana Wu; Walter C Willett; Edward L Giovannucci; Brian M Wolpin; Jeffrey A Meyerhardt; Charles S Fuchs; Kimmie Ng
Journal:  J Natl Cancer Inst       Date:  2019-02-01       Impact factor: 13.506

4.  Identification of key candidate genes and pathways associated with colorectal aberrant crypt foci-to-adenoma-to-carcinoma progression.

Authors:  Setareh Fayazfar; Afsaneh Arefi Oskouie; Akram Safaei; Hakimeh Zali; Ehsan Nazemalhosseini Mojarad
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2021

5.  Oncolytic Virus Affects the RAS Pathway in Cancer: RNA Sequence Analysis.

Authors:  Avishai Samouha; Elisha J Fogel; Sanjay Goel; Radhashree Maitra
Journal:  J Oncol Res Ther       Date:  2021-10-27

6.  Phospholipase Cδ1 induces E-cadherin expression and suppresses malignancy in colorectal cancer cells.

Authors:  Reiko Satow; Tamaki Hirano; Ryosuke Batori; Tomomi Nakamura; Yumi Murayama; Kiyoko Fukami
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-02       Impact factor: 11.205

7.  β-catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer.

Authors:  Hani Lee; Nayoung Kim; Young Ji Yoo; Hyejin Kim; Euna Jeong; SeokGyeong Choi; Sung Un Moon; Seung Hyun Oh; Gordon B Mills; Sukjoon Yoon; Woo-Young Kim
Journal:  Oncogene       Date:  2018-06-12       Impact factor: 9.867

8.  Identification of mutant K-RAS in pituitary macroadenoma.

Authors:  Veronica Aran; Manoela Heringer; Paulo Jose da Mata; Leandro Kasuki; Renan Lyra Miranda; Felipe Andreiuolo; Leila Chimelli; Paulo Niemeyer Filho; Monica Roberto Gadelha; Vivaldo Moura Neto
Journal:  Pituitary       Date:  2021-05-05       Impact factor: 4.107

9.  Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.

Authors:  Anna A Marusiak; Natalie L Stephenson; Hayeon Baik; Eleanor W Trotter; Yaoyong Li; Karen Blyth; Susan Mason; Phil Chapman; Lorena A Puto; Jon A Read; Claire Brassington; Hannah K Pollard; Chris Phillips; Isabelle Green; Ross Overman; Matthew Collier; Ewelina Testoni; Crispin J Miller; Tony Hunter; Owen J Sansom; John Brognard
Journal:  Cancer Res       Date:  2015-12-04       Impact factor: 12.701

10.  Immune-Related Nine-MicroRNA Signature for Predicting the Prognosis of Gastric Cancer.

Authors:  Jingxuan Xu; Jian Wen; Shuangquan Li; Xian Shen; Tao You; Yingpeng Huang; Chongyong Xu; Yaping Zhao
Journal:  Front Genet       Date:  2021-07-05       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.